The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile.
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial / Salvarani, C., Dolci, G., Massari, M., Merlo, D.F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., Ballerini, P.F., Sciascia, R., Zammarchi, L., Para, O., Scotton, P.G., Inojosa, W.O., Ravagnani, V., Salerno, N.D., Sainaghi, P.P., Brignone, A., et al.. - In: JAMA INTERNAL MEDICINE. - ISSN 2168-6106. - ELETTRONICO. - (2021), pp. 1-1. [10.1001/jamainternmed.2020.6615]
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial
Cavuto, Silvio;Zammarchi, Lorenzo;Para, Ombretta;
2021
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jamainternal_salvarani_2020_oi_200094_1609365347.37772.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
484.68 kB
Formato
Adobe PDF
|
484.68 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
